May 2013

Document Type


Degree Name



Dept. of Biomedical Engineering


Oregon Health & Science University


Cancer is a hypercoagulable state. Thrombosis is the second leading cause of death in cancer, and development of thrombosis confers a worse prognosis for patients with cancer. Conventional anticoagulants are effective at preventing thrombosis (thromboprophylaxis) in patients with cancer, yet thromboprophylaxis is not safe for routine administration in cancer care. A biomarker to identify patients with cancer at risk to develop thrombosis would allow personalized thromboprophylaxis for those in need, while sparing the risks of anticoagulation for those not at elevated risk to develop thrombosis. An increased incidence of thrombosis has been observed in patients with metastatic cancer and acute leukemia. Undifferentiated myeloid leukemia cells are present in the peripheral blood of patients with acute myelogenous leukemia (AML). Thrombosis in AML has been associated with elevated counts of leukemia cells in the peripheral blood. In metastatic cancer, tumor cells are shed into the vascula




School of Medicine



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.